- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03966742
Doxorubicin Eluting Intra-arterial Embolization for Aggressive Desmoid Fibromatosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Desmoid Fibromatoses (DF) are locally aggressive lesions associated with substantial morbidity and potentially mortality, due to invasion of adjacent neurovascular structures and vital organs. They have no potential for metastasis. Histologically, they are characterised by mature fibroblasts within a matrix of abundant fibrous stroma. While 5-15% of cases are seen in patients with Familial Adenomatous Polyposis (FAP) syndrome, the vast majority arise sporadically.
The etiology of Desmoids remains poorly understood and the therapeutic approaches in their management remain very diverse. For resectable lesions, surgery is recommended but reported cure rates range broadly from 12-80%. Systemic treatments range from non-steroidal anti-inflammatories and anti-estrogenic therapy to targeted tyrosine kinase inhibitors and cytotoxic chemotherapy, most commonly methotrexate, vinblastine and doxorubicin.
Doxorubicin is an anthracycline with demonstrated efficacy in treating desmoids at systemic IV doses of 50- 75mg/m2 over 3-4 week cycles. Extended use is limited by dose - dependent cardiotoxicity which can be seen in up to 36% of patients receiving doses in excess of 550mg/m2. Delayed cardiotoxicity is particularly common and less predictable among pediatric cancer survivors.
Selective trans-arterial chemo-embolization (TACE) is a method to achieve high tissue drug concentration with minimal systemic toxicity. Historically, this has been achieved by mixing doxorubicin with embolic agents such as lipiodol or gelatin sponge in the treatment of hepatocellular carcinoma (HCC).
Drug-eluting microbeads (DEB) ionically loaded with doxorubicin have shown sustained release in TACE target tissues with substantially lower serum drug concentrations when compared to lipiodol TACE.
The present study utilizes DEB's loaded with Doxorubicin delivered into the target DF tissue via selective arterial embolization by angiographic technique. This study follows a successful feasibility study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Petach-Tikva, Israel
- Rabin Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 3-80 years.
- Histologically confirmed diagnosis of Desmoids Fibromatosis.
- After at least one systemic treatment line. Standard first line systemic treatment may include: Methotrexate, Vinblastine, Doxorubicin, Liposomal Doxorubicin (Doxil), NSAIDS or hormonal treatment. If first line treatment is renounced, this treatment decision must be documented. Considering the trend of avoiding surgical treatment, the documentation must include that the treatment decision is not associated to the resectability of the tumor.
- Karnofsky performance status (PS)>50% for patients older than 16 years or Lansky PS >50% for patients under 16 years.
- At least one measurable lesion, with a long diameter of at least 30mm, with an anatomical location accessible for endovascular treatment.
- T2 signal increase on MRI.
No evidence of prior treatment toxicity, adequate washout period after prior treatment:
- 14 days after myelosuppressive chemotherapy treatment.
- 7 days after GCSF (Granulocyte colony-stimulating factor), 14 days after Neulastim.
- 7 days after targeted/biologic treatment.
- Female patients of childbearing potential must be willing to use an adequate method of contraception (hormonal, barrier or abstinence) for the treatment period and up to 90 days after the treatment completion.
- Willing and able to provide written informed consent for the trial.
Exclusion Criteria:
- Participation in another interventional study.
- Congestive heart failure, characterised by LVEF (Left Ventricular Ejection Fraction) < 50% or Shortening fracture < 27%.
- Previous treatment with anthracycline of a accumulative dose of more than 360 mg/m2.
- History of allergic reaction attributed to Doxil or doxorubicin treatment.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III or IV), cardiac arrhythmia, or psychiatric illness, social situations that would limit compliance with study requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Doxorubin-eluting particle embolization for treatment of Desmoid Fibromatosis.
|
Delivery of Doxorubicin selectively into Desmoid Fibromatosis utilizing its vascular supply as a conduit, and ionic loading the doxorubicin onto embolized particles as the drug delivery vehicle. Maximal dose is 75 mg/m2 and at least 50 mg. The bead size is 75-300 Mµ in a 2 CC syringe. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate of tumor size.
Time Frame: At baseline ; 6-10 weeks after each treatment
|
Response to treatment.
Measured by change in tumor size according to RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1 criteria.
|
At baseline ; 6-10 weeks after each treatment
|
Objective response rate of tumor biological activity.
Time Frame: At baseline ; 6-10 weeks after each treatment
|
Response to treatment.
Tumor biological activity measured by change in MRI T2 signal intensity.
|
At baseline ; 6-10 weeks after each treatment
|
Patient reported outcomes.
Time Frame: At baseline ; 6-10 weeks after each treatment
|
Change in clinical symptoms measured by standard clinical patient questionnaires - EORTC QLQ-C30. (Quality of Life Questionnaire). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high level of functioning, a high score for the global health status / QoL represents a high QoL. Similarly, a high score for a symptom scale represents a high level of symptomatology. |
At baseline ; 6-10 weeks after each treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse event profile (safety)
Time Frame: At baseline ; 6-10 weeks
|
Treatment safety measured by standard patient questionnaires and clinical evaluation using CTCAE (Common Terminology Criteria for Adverse Events) version 5.0.
|
At baseline ; 6-10 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics of Doxorubicin
Time Frame: 5 minutes, 30 minutes, 1 hour, 12 hours, 24 hours after treatment procedure
|
Measurements of blood Doxorubicin concentration (mg/ml) over time, after treatment.
|
5 minutes, 30 minutes, 1 hour, 12 hours, 24 hours after treatment procedure
|
Exploratory biomarkers
Time Frame: At baseline ; 6-10 weeks
|
Immunohistochemistry assay assessing the staining pattern (marked as negative to mildly or strongly positive) for: beta-catenin, keratin, SMA (smooth muscle actin).
Ki-67 staining will be scored by percentage.
|
At baseline ; 6-10 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RMC-0485-17
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Desmoid Fibromatosis
-
Children's Oncology GroupNational Cancer Institute (NCI); SpringWorks Therapeutics, Inc.Active, not recruitingDesmoid Fibromatosis | Recurrent Desmoid Fibromatosis | Unresectable Desmoid FibromatosisUnited States, Canada, Puerto Rico, Australia, New Zealand
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...Ministero della Salute, ItalyUnknownDesmoid-type FibromatosisItaly
-
Memorial Sloan Kettering Cancer CenterRecruiting
-
National Cancer Institute (NCI)CompletedDesmoid FibromatosisUnited States, Canada
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...Associazione Italiana per la Ricerca sul CancroUnknownDesmoid Type-fibromatosisItaly
-
Erasmus Medical CenterRadboud University Medical Center; Royal Marsden NHS Foundation Trust; The Netherlands...CompletedDesmoid Tumor | Desmoid-type FibromatosisUnited Kingdom, Netherlands
-
Blokhin's Russian Cancer Research CenterNot yet recruitingDesmoid Fibromatosis | Desmoid Tumor | DesmoidRussian Federation
-
Oxford University Hospitals NHS TrustSurgical Intervention Trials Unit (trial oversight); NIHR Direct Delivery Team... and other collaboratorsRecruitingSoft Tissue Sarcoma | Desmoid; AbdominalUnited Kingdom
-
National Cancer Institute (NCI)CompletedDesmoid Tumors | Aggressive FibromatosisUnited States
-
European Organisation for Research and Treatment...CompletedDesmoid TumorFrance, Switzerland, Belgium, United Kingdom, Poland, Netherlands, Germany
Clinical Trials on Drug Eluting Bead Embolization (DEB) for Desmoid Fibromatosis
-
Abramson Cancer Center at Penn MedicineGuerbetActive, not recruitingLiver Metastases | Neuroendocrine Tumor, MalignantUnited States, Canada, Italy, Argentina
-
Air Force Military Medical University, ChinaUnknown
-
Zhejiang UniversityActive, not recruiting
-
Second Affiliated Hospital of Guangzhou Medical...RecruitingHepatocellular Carcinoma Non-resectableChina
-
Memorial Sloan Kettering Cancer CenterBristol-Myers SquibbActive, not recruiting
-
The Christie NHS Foundation TrustNot yet recruitingColorectal Cancer Metastatic | Liver MetastasesUnited Kingdom
-
University of British ColumbiaCompleted
-
Washington University School of MedicineTerminatedHepatocellular CarcinomaUnited States
-
Translational Research in OncologyBayerRecruitingCarcinoma, HepatocellularKorea, Republic of, United States, Taiwan, Spain, Japan, France, Georgia, Germany, Turkey, Italy, Belgium, Hong Kong, Serbia
-
General Administration of Military Health, TunisiaB. Braun Medical International Trading Company Ltd.RecruitingCoronary Artery Disease (CAD) | De Novo Stenosis | Percutaneous Coronary Intervention (PCI)Tunisia